GCM
HAE icon

Geneva Capital Management’s Haemonetics HAE Stock Holding History

Geneva Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-256,603
Closed -$10.8M – 133
2013
Q4 		$10.8M Sell
256,603
-11,830
-4% -$487K 0.24% 95
2013
Q3 		$10.7M Buy
268,433
+34,264
+15% +$1.44M 0.25% 93
2013
Q2 		$9.68M Buy
+234,169
New +$9.48M 0.19% 87

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geneva Capital Management's HAE Position: Q1 2014 in Review

Geneva Capital Management sold out of Haemonetics (HAE) in Q1 2014, closing a stake of 256,603 shares — an estimated $10.8M sold.

Geneva Capital Management first reported a position in HAE in Q2 2013 and held it in 3 quarters. The position peaked at $10.8M in Q4 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q1 2014.

  • Geneva Capital Management reported no remaining Haemonetics position as of Q1 2014 after selling out during the quarter.
  • Geneva Capital Management sold 256,603 Haemonetics shares in Q1 2014, an estimated $10.8M.
  • Geneva Capital Management first reported a position in Haemonetics in Q2 2013 and held it in 3 quarters.
  • Geneva Capital Management's Haemonetics position peaked at $10.8M in Q4 2013.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q1 2014.

Based on Geneva Capital Management's 13F filing for Q1 2014, filed 12 May 2014.